Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Oct 04 10:11AM ET
53.87
Dollar change
-0.33
Percentage change
-0.62
%
IndexS&P 500 P/E- EPS (ttm)-3.26 Insider Own0.08% Shs Outstand2.03B Perf Week5.80%
Market Cap109.21B Forward P/E7.73 EPS next Y6.97 Insider Trans0.00% Shs Float2.03B Perf Month8.16%
Income-6541.00M PEG- EPS next Q1.58 Inst Own77.23% Short Float1.08% Perf Quarter34.70%
Sales46.51B P/S2.35 EPS this Y-90.13% Inst Trans-0.74% Short Ratio1.58 Perf Half Y4.96%
Book/sh8.39 P/B6.42 EPS next Y840.14% ROA-6.95% Short Interest21.79M Perf Year-5.05%
Cash/sh3.28 P/C16.41 EPS next 5Y-4.81% ROE-26.70% 52W Range39.35 - 57.65 Perf YTD4.98%
Dividend Est.2.39 (4.44%) P/FCF8.44 EPS past 5Y5.14% ROI-9.72% 52W High-6.56% Beta0.44
Dividend TTM2.37 (4.40%) Quick Ratio1.02 Sales past 5Y16.92% Gross Margin56.12% 52W Low36.89% ATR (14)1.25
Dividend Ex-DateOct 04, 2024 Current Ratio1.16 EPS Y/Y TTM-186.04% Oper. Margin17.58% RSI (14)70.12 Volatility2.60% 2.46%
Employees34100 Debt/Eq3.17 Sales Y/Y TTM2.93% Profit Margin-14.06% Recom2.86 Target Price52.01
Option/ShortYes / Yes LT Debt/Eq2.96 EPS Q/Q-16.04% Payout59.82% Rel Volume0.99 Prev Close54.20
Sales Surprise5.73% EPS Surprise27.81% Sales Q/Q8.69% EarningsJul 26 BMO Avg Volume13.79M Price53.87
SMA207.23% SMA509.54% SMA20012.77% Trades Volume2,036,149 Change-0.62%
Date Action Analyst Rating Change Price Target Change
Jul-29-24Downgrade Barclays Overweight → Equal Weight $41
Mar-11-24Downgrade Societe Generale Buy → Hold
Feb-06-24Downgrade Redburn Atlantic Buy → Neutral $77 → $54
Jan-03-24Downgrade BofA Securities Buy → Neutral $68 → $60
Nov-15-23Downgrade Cantor Fitzgerald Overweight → Neutral $68 → $55
Nov-09-23Initiated Deutsche Bank Hold $55
Nov-02-23Downgrade Daiwa Securities Outperform → Neutral $68 → $54
Oct-27-23Upgrade HSBC Securities Reduce → Hold $55 → $53
Oct-27-23Downgrade William Blair Outperform → Mkt Perform
Oct-27-23Downgrade BMO Capital Markets Outperform → Market Perform $60
Oct-03-24 05:35PM
01:11PM
Sep-30-24 07:00AM
Sep-27-24 07:38PM
04:18PM
02:17PM Loading…
02:17PM
11:58AM
11:06AM
11:00AM
09:44AM
09:36AM
06:59AM
05:59AM
Sep-26-24 09:05PM
07:20PM
08:29PM Loading…
Sep-25-24 08:29PM
Sep-18-24 06:59AM
Sep-16-24 05:25AM
Sep-15-24 08:55AM
Sep-12-24 06:59AM
Sep-10-24 05:45PM
Sep-09-24 06:59AM
Sep-08-24 02:30AM
Sep-06-24 07:00AM
Sep-01-24 03:33AM
Aug-28-24 06:19PM
Aug-27-24 06:59AM
Aug-26-24 06:59AM
Aug-21-24 06:59AM
Aug-19-24 06:59AM
07:30AM Loading…
Aug-16-24 07:30AM
Aug-15-24 05:30PM
03:48PM
12:34PM
10:49AM
07:49AM
Aug-08-24 06:30AM
Jul-29-24 06:30AM
Jul-27-24 11:31AM
Jul-26-24 07:06PM
01:26PM
11:33AM
10:36AM
08:55AM
06:59AM
04:57AM
Jul-25-24 06:03PM
Jul-19-24 06:59AM
Jul-11-24 02:23PM
Jul-10-24 12:00PM
Jul-09-24 07:40AM
Jul-08-24 06:59AM
06:43AM
Jul-05-24 06:45AM
Jun-30-24 10:13AM
Jun-27-24 01:14PM
Jun-23-24 01:38PM
Jun-21-24 07:30PM
06:59AM
Jun-20-24 06:59AM
Jun-19-24 02:17PM
01:09PM
Jun-18-24 04:16PM
06:59AM
Jun-17-24 03:27PM
09:45AM
Jun-14-24 06:45PM
Jun-13-24 04:46PM
09:00AM
Jun-12-24 01:50AM
Jun-11-24 11:52AM
10:00AM
Jun-10-24 12:00PM
Jun-08-24 09:00AM
Jun-05-24 09:49AM
09:42AM
09:30AM
07:00AM
Jun-04-24 08:00AM
06:59AM
Jun-03-24 10:13AM
08:00AM
Jun-01-24 08:00AM
May-31-24 08:04AM
May-30-24 11:51AM
11:05AM
06:10AM
May-29-24 06:59AM
May-28-24 01:24PM
10:15AM
May-27-24 06:13AM
May-23-24 07:22PM
05:05PM
12:03PM
06:59AM
May-22-24 01:44PM
11:15AM
03:30AM
May-21-24 08:45AM
07:45AM
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gallman CariEVP, Corporate AffairsOct 02 '24Option Exercise0.004,55806,667Oct 03 06:33 PM
Gallman CariEVP, Corporate AffairsAug 01 '24Option Exercise0.001,06102,493Aug 05 06:01 PM
Shanahan KarinEVP, Glob. Prod. Dev. & SupplyApr 01 '24Option Exercise0.003,30606,532Apr 02 06:45 PM
Lenkowsky AdamEVP, Chief Commercial OfficerMar 10 '24Option Exercise0.0015,016013,859Mar 12 09:54 PM
LEUNG SANDRAEVP, General CounselMar 10 '24Option Exercise0.0046,7840371,312Mar 12 09:43 PM
Plenge Robert MEVP, Chief Research OfficerMar 10 '24Option Exercise0.009,143015,182Mar 12 09:21 PM
Poole Ahn AmandaEVP, Chief Human ResourcesMar 10 '24Option Exercise0.005,45804,841Mar 12 09:11 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Mar 10 '24Option Exercise0.0038,388080,256Mar 12 08:40 PM
Holzer Phil MSVP and ControllerMar 10 '24Option Exercise0.005,520014,916Mar 12 08:31 PM
Hoch LynellePresident, Cell Therapy Org.Mar 10 '24Option Exercise0.004,35103,781Mar 12 08:01 PM
Gallman CariEVP, Corporate AffairsMar 10 '24Option Exercise0.002,76102,655Mar 12 08:00 PM
BOERNER CHRISTOPHER S.Chief Executive OfficerMar 10 '24Option Exercise0.0054,6380129,769Mar 12 07:58 PM
Elkins David VEVP, Chief Financial OfficerMar 10 '24Option Exercise0.0064,3260225,111Mar 12 05:43 PM
Caforio GiovanniExecutive Chair of the BoardMar 10 '24Option Exercise0.00190,1300529,662Mar 12 05:42 PM
Meyers Gregory ScottEVP, Chief Digital & Tech Off.Feb 01 '24Option Exercise0.002,54306,040Feb 05 07:10 PM
BOERNER CHRISTOPHER S.Chief Executive OfficerDec 05 '23Buy49.782,00099,56082,672Dec 07 06:06 PM
Plenge Robert MEVP, Chief Research OfficerDec 02 '23Option Exercise0.0061607,200Dec 05 06:23 PM
Elkins David VEVP, Chief Financial OfficerDec 02 '23Option Exercise0.008,7920172,342Dec 05 06:22 PM
BOERNER CHRISTOPHER S.Chief Executive OfficerDec 02 '23Option Exercise0.002,638082,022Dec 05 06:21 PM
BOERNER CHRISTOPHER S.Chief Executive OfficerNov 28 '23Buy48.863,071150,04979,384Nov 30 06:32 PM
Samuels Theodore R. IIDirectorNov 20 '23Buy49.818,500423,38535,500Nov 21 07:01 PM